An observational study in Celiac Disease, Autoimmune Enteropathy and Inflammatory Bowel Diseases, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Celiac Disease with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Celiac Disease · France.
Among the 13 studies in Celiac Disease with a site in France, this one is the only one that started in 2020, is one of 6 observational ones, and was the 5th registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →3 of the 13 studies in Celiac Disease with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Fondation Lenval · Sites in France
Ages 2–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 200 is close to the median of 185 across 134 observational studies indexed under Celiac Disease.
Median enrollment 44 across the 7 interventional studies, 327 across the 6 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 1 study filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Celiac Disease with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.
Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with active coeliac disease
Genetic: Blood sample collection; gastrointestinal biopsy
Patients with coeliac disease on gluten free diet
Genetic: Blood sample collection; gastrointestinal biopsy
Patients with refractory coeliac disease of type I
Genetic: Blood sample collection; gastrointestinal biopsy
Patients with refractory coeliac disease of type II
Genetic: Blood sample collection; gastrointestinal biopsy
Patients with intestinal lymphoproliferations
Genetic: Blood sample collection; gastrointestinal biopsy
Patients with non coeliac immune-mediated enteropathy
Genetic: Blood sample collection; gastrointestinal biopsy
Patients without neoplastic or inflammatory intestinal disease
Genetic: Blood sample collection; gastrointestinal biopsy
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Intestinal Lymphocytes count
Lymphocytes isolation
Time frame: Baseline
DNA sequencing
Targeted Next Generation sequencing
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Feb 2030, 120 months after the start.
Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →